Janux Therapeutics’ Post

Thoughts on this? >> #ASCO24: GenFleet highlights Phase 2 data on KRAS/EGFR combo in lung cancer  >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #biotech #pharma #healthcare #pharmaceutical

The Theranojet®ARA is a shielded injection system developed by Lemer Pax for the safe and precise administration of radiopharmaceuticals in theranostic applications. It features advanced radiation protection, ease of use, and secure patient administration. Key Features: 1. Radiation Protection: The system employs lead and lead glass shielding to minimize radiation exposure to medical personnel during preparation, administration, and disposal of radiopharmaceuticals . 2. Ease of Use: With its mobile design, removable drip tray, and contamination tray, the Theranojet®ARA is easy to maneuver and clean . 3. Patient Safety: The configurable pump detects occlusions and air bubbles, preventing extravasation and ensuring safe injection . 4. Successful Implementation: Used effectively at the Beaujon AP-HP Hospital in Paris for Lutetium-177 therapies, the system significantly reduces radiation exposure for healthcare staff . Importance of Minimizing Contamination and Residuals: Injecting a therapeutic radioactive material like Lutetium-177, which has a long half-life, without contamination and minimal residuals is crucial for several reasons: 1. Safety of Medical Personnel: Reducing contamination prevents unnecessary radiation exposure to healthcare workers, which is essential for maintaining their safety and health . 2. Patient Safety: Ensuring no residuals or contamination minimizes the risk of unintended radiation doses to patients, which can lead to complications or ineffective treatment. 3. Environmental Safety: Proper handling and disposal of radioactive materials prevent environmental contamination, protecting the broader community and ecosystem. 4. Therapeutic Efficacy: Accurate dosing without residuals ensures that the patient receives the correct therapeutic dose, optimizing treatment effectiveness for conditions like metastatic neuroendocrine tumors and prostate cancer . The Theranojet®ARA’s design addresses these concerns by providing a safe, efficient, and contamination-free method for administering radiopharmaceuticals, making it a vital tool in modern nuclear medicine.

Thoughts on this? >> #ASCO24: GenFleet highlights Phase 2 data on KRAS/EGFR combo in lung cancer  >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #biotech #pharmaceutical #productmarketing #pharma

Precision Medicine + Free Chemotherapy Side Effects + Broad-Spectrum : Antican Offers an Innovative Anti-Cancer Hope   Patients: Dream of effective anti-cancer drugs with no side effects. Investors & Pharma: Seeking new drugs with broader range of indications, benefiting more patients.   "Broad-Spectrum + Precision Medicine + Free Chemotherapy Side Effects Anti-Cancer New Drug" is eagerly awaited by everyone! Meeting patient needs is the most critical core. I invite you to contact / message me. Your support to create new hope for cancer patients is important.     # Broad-Spectrum # Precision Medicine # Free Chemotherapy Side Effects # Anti-Cancer New Drug # Antican # Hope

It appears that Keytruda is no longer the sole standout in Merck's product lineup. Two years after initially receiving FDA approval for treating the rare von Hippel-Lindau (VHL) disease, Merck is now aiming to broaden Welireg's applicability and elevate it to blockbuster status. Acquired through a $1.1 billion purchase of Peloton Therapeutics in 2019, Welireg demonstrated improved progression-free survival rates for certain renal cell carcinoma (RCC) patients in a phase 3 trial, outperforming Novartis' Afinitor. #oncology #oncologyresearch #clinicaltrials #clinicalresearch #cra #clinicalresearchassociate https://lnkd.in/gz9V-Ciy

Join us for an enlightening conversation with Brian Fiske, who holds the distinguished positions of both Portfolio Member and Scientific Advisory Board Member at Alix Ventures, as he shares his expert insights on the evolving landscape of oncology care. #CancerTherapyInnovation #MythicTherapeutics #HealthcarePodcast #BiotechInsights

Learn more about the solutions making oncology practice management more manageable. From smarter comprehensive drug management and oncology clinical management technology to insightful advisors and tools, discover the McKesson difference.

Advances and challenges in the development of ADCs is revolutionizing cancer therapy. Access your free article in partnership with ICON plc: https://ow.ly/E0sS50SiY8s. Antibody-Drug Conjugates (ADCs) are notoriously tricky to develop, due to their delicate nature and the barriers facing their delivery. This article highlights key obstacles in the development of ADCs and why the future remains bright for this targeted therapy. #CancerTherapy #ADCs #DrugDevelopment #OncologyResearch #Biopharma #TargetedTherapy #PharmaPartnership #HealthcareAdvances

Recently, Senior Biotech Analyst, John Vandermosten, had an insightful conversation with our CEO, James G. Cullem. One question that brought a smile to James' face was John's inquiry about M&A in the biotech sector. Check out their conversation below 👇

Desmoid tumors are a rare type of connective tissue tumor. They aren’t cancerous, but can be debilitating. Up until recently, there had never been a prescribed treatment for these tumors. But that changed in November, when the FDA approved the drug Osgivio, manufactured by SpringWorks Therapeutics. Although originally developed for the treatment of Alzheimer’s disease, Osgivio was never approved for that condition. However, it showed great promise for treating desmoid tumors, which inspired further research. Osgivio shrinks desmoid tumors, reducing pain and improving mobility. Scientists say the approval is incredibly exciting for those suffering from this painful condition. Source: https://hubs.li/Q02dHztv0 #osgivio #desmoidtumors #FDAapproval #healthnews #foodanddrugadministration #SpringWorksTherapeutics #drugevaluationandresearch